RPRX250117P27500
- 2.50
- 0.000.00%
Royalty Pharma Newsroom
Looking For Yields: Comcast, Royalty Pharma And Regions Financial Are Consistent Moneymakers
Pinning Down Royalty Pharma Plc's (NASDAQ:RPRX) P/S Is Difficult Right Now
Royalty Pharma Plc (NASDAQ:RPRX) Is Favoured by Institutional Owners Who Hold 72% of the Company
Jim Cramer Calls Royalty Pharma (RPRX) 'Disappointing' But Recommends Holding – 'I Want You To Stick With It'
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Royalty Pharma (RPRX) Gets a Buy From TD Cowen
Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock
Here's Why Agios Stock Plummeted More Than 20% on Monday
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
First Solar and 2 More Cheap Stocks to Consider
Insiders At Royalty Pharma Sold US$42m In Stock, Alluding To Potential Weakness
How Royalty Pharma, Open Text And VICI Properties Can Put Cash In Your Pocket
Royalty Pharma to Present at Upcoming Investor Conferences
Why Royalty Pharma (RPRX) Is the Cheapest Stock to Buy on Robinhood?
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $39
BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $39
Strong Buy Rating for Royalty Pharma: Robust Revenue Growth and Promising Pipeline
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma To Go Ex-Dividend On November 15th, 2024 With 0.21 USD Dividend Per Share
November 13th (Eastern Time) - $Royalty Pharma(RPRX.US)$ is trading ex-dividend on November 15th, 2024.Shareholders of record on November 15th, 2024 will receive 0.21 USD dividend per share on
Royalty Pharma's (NASDAQ:RPRX) Solid Earnings May Rest On Weak Foundations